Skip to main content

New Products

  • FDA approves J&J's Olysio for hepatitis C

    TITUSVILLE, N.J. — The Food and Drug Administration has approved a new treatment made by Johnson & Johnson for hepatitis C, the drug maker said.

  • Pfizer launches Robitussin Maximum Strength Cough + Congestion DM

    MADISON, N.J. — Pfizer on Monday launched Robitussin Maximum Strength Cough + Congestion DM, a new liquid-filled capsule that helps control cough on-the-go. "This formulation not only harnesses the power of Maximum Strength Robitussin cough liquid, but is a convenient option for those hitting the road or boarding a plane this holiday season," the company stated.

    The company noted that whether traveling cross country or staying close to home, families can track when cough activity spikes in their local area via the Robitussin COUGHCAST tool. 

  • Movit Energy Gummies launch, target athletic consumers

    MEAD, Wash. — Movit Energy Gummies recently launched its signature product targeting active sports enthusiasts with an energy product in gummy format. 

    Movit comes in a snack-size packet typically containing 11 gummies, which altogether contain 60 calories, in one of two flavors — citrus or berry. The proprietary formula includes such ingredients as Brazilian guarana, co-enzyme Q10, D-ribose, vitamin C, taurine, protein and a full complement of B vitamins.

    The energy formula meets high school and NCAA guidelines, the company stated.

  • Sandoz launches authorized generic version of PharmaDerm's Solaraze

    PRINCETON, N.J. — Sandoz has launched an authorized generic version of a topical drug for treating actinic keratosis, the company said.

    Sandoz, the generics arm of Swiss drug maker Novartis, announced the launch of authorized generic diclofenac gel in the 3% strength. The drug is a version of PharmaDerm's Solaraze.

  • Teva launches generic drug for cystic fibrosis patients

    JERUSALEM — Teva Pharmaceutical Industries has launched its generic version of a drug for patients with cystic fibrosis, the Israeli drug maker said Thursday.

    Teva announced the launch of tobramycin inhalation solution, a generic version of Novartis' drug Tobi. The Food and Drug Administration approved Teva's product last month. The drug is used to treat CF in patients whose lungs contain bacteria called Pseudomonas aeroginosa.

    Tobi had sales of about $350 million during the 12-month period that ended in June, according to IMS Health.

     

  • FDA gives regular approval to Pfizer's Xalkori

    NEW YORK — The Food and Drug Administration has granted regular approval to a new drug made by Pfizer for treating a form of lung cancer, the drug maker said.

  • Diplomat added to limited-distribution network for Cornerstone Therapeutics' Bethkis

    FLINT, Mich. — Cornerstone Therapeutics has added specialty pharmacy Diplomat to its limited-distribution network for a newly approved treatment for cystic fibrosis, Diplomat said Friday.

    Diplomat will distribute Bethkis (tobramycin inhalation solution), which received Food and Drug Administration approval in October for treating chronic bacterial lung infections caused by P. aeruginosa in cystic fibrosis patients.

  • Honest Tea introduces Unsweet Lemon Tea

    BETHESDA, Md. — Honest Tea, maker of organic bottled tea, is rolling out Unsweet Lemon Tea nationwide, the company announced. The zero-calorie beverage is brewed with organic, Fair Trade-certified tea leaves and flavored with organic lemon extract.  

X
This ad will auto-close in 10 seconds